# US 2008/0188464 A1 · Combinations of Dopamine D2 Receptor Blockade with Norepinephrine Reuptake Inhibition and With Norepinephrine Alpha 2 Receptor Blockade

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188464 A1
- Document ID: US20080188464A1
- Status: Published application
- Kind: A1
- Application number: 12/024,950
- Filed: 2008-02-01
- Published: 2008-08-07
- Earliest claimed: 2007-02-01
- Inventors: Alan I. Green; David Chau
- Web page: https://patentgrep.com/patent/US20080188464A1

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/451: having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/30: for treating abuse or dependence
- A61P 25/32: Alcohol-abuse
- A61P 25/34: Tobacco-abuse
- A61P 25/36: Opioid-abuse
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating and or preventing substance abuse/dependence, and alcohol abuse/dependence in particular. Combinations of medications are also disclosed.

## Claims

### Claim 1

A method of treating a patient with, or at risk for, alcohol or other substance abuse or dependence, by administering to the patient a composition exhibiting a combination of
a) dopamine D2 receptor blockade (antagonism); and
b) norepinephrine reuptake inhibition.

### Claim 2 (depends on 1)

The method of claim 1 in which the composition further exhibits norepinephrine alpha 2 receptor blockade (antagonism).

### Claim 3 (depends on 1)

The method of claim 1 in which the substances of abuse includes one or more of the following: alcohol, one or more opioids, cannabis, cocaine, amphetamines, tobacco.

### Claim 4 (depends on 3)

The method of claim 3 in which the opioid is heroin, oxyContin®, or both.

### Claim 5 (depends on 1, 2)

The method of claim 1 or claim 2 in which the D2 receptor blockade is a weak dopamine D2 receptor antagonist (blocker).

### Claim 6 (depends on 1)

The method of claim 1 in which the patient does not exhibit a co-occurring psychiatric disorder such as schizophrenia or bipolar disorder.

### Claim 7 (depends on 1)

The method of claim 1 in which the patient exhibits a co-occurring psychiatric disorder such as schizophrenia or bipolar disorder.

### Claim 8 (depends on 1)

The method of claim 1 in which the composition comprises as the dopamine D2 receptor antagonist activity, a drug selected from the group comprising risperidone, paliperidone, haloperidol, olanzapine, quetiapine, ziprasidone, aripiprazole, iloperidone, fluphenazine, chlorpromazine, trifluoperizine, molindone, perphenazine, mesoridazine, raclopride, sulpiride, amisulpiride.

### Claim 9 (depends on 2)

The method of claim 2 in which the composition comprises, as the norepinephrine alpha 2 receptor antagonist, idazoxan, yohimbine, atipamezole, mirtazapine, mianserin, phenoxybenzamine, buspirone, mianserin,

### Claim 10 (depends on 1)

The method of claim 1 in which the composition comprises, as the norepinephrine reuptake inhibition, desipramine, reboxetine, nortriptyline, atamoxetine, maprotiline, nisoxetine, imipramine, bupropion, ketamine, n-desalkylquetiapine.

### Claim 11

A medicament comprising a) dopamine D2 receptor blockade (antagonism); and b) norepinephrine reuptake inhibition.

### Claim 12 (depends on 11)

The medicament of claim 11 further comprising a norepinephrine alpha 2 receptor blockade (antagonism).
